AI-generated personalized bipolar management plans present growth opportunities driven by rising mental health awareness, ...

Clinical trials in human beings are in progress on using heart drugs for the treatment of bipolar disorder following its ...

Teva Pharmaceuticals and Medincell have gained approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone), a once-a-month extended-release injectable suspension to treat adult ...

Bipolar disorder treatment often includes some combination of medications like mood stabilizers and antidepressants alongside therapy.

The number of people suffering from depression or bipolar disorders in Korea has surged, with cases of each of the conditions ...

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

Teva Pharmaceuticals and Medincell recently announced that the FDA has approved UZEDY® (risperidone), a once-monthly ...

Today, BD², or Breakthrough Discoveries for thriving with Bipolar Disorder, announced its third round of Discovery Research ...

BD² recently announced a fourth round of funding opportunities, inviting teams to apply for up to $4.5 million per grant to undertake groundbreaking research into the genetic, molecular, cellular, ...

Xenon Pharmaceuticals (($XENE)) announced an update on their ongoing clinical study. Study Overview: Xenon Pharmaceuticals is conducting a Phase 3 ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

The Icahn School of Medicine at Mount Sinai is pleased to announce it has received a three-year, $4.5 million grant from BD2: ...